We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients

By MedImaging International staff writers
Posted on 28 Sep 2023
Print article
Image: Imaging entire body instead of only the primary cancer site can provide a total estimate of HER2 expression (Photo courtesy of 123RF)
Image: Imaging entire body instead of only the primary cancer site can provide a total estimate of HER2 expression (Photo courtesy of 123RF)

Around 20% of women diagnosed with breast cancer show overexpression of human epidermal growth factor receptor 2 (HER2), making it a key therapy target for new as well as recurring cases. Yet, treatments that target HER2 often fail because breast cancer is not a one-size-fits-all disease; even within the same patient, HER2 levels can change. Now, new research indicates that a novel imaging agent, 68Ga-ABY-025, may help address this challenge by predicting early metabolic responses to HER2-specific therapies in patients with HER2-positive metastatic breast cancer. This agent, when used with PET/CT scans, can offer whole-body quantification of HER2 levels, aiding in treatment planning and potentially sparing patients from the unnecessary side effects of drugs.

Researchers at Uppsala University (Uppsala, Sweden) investigated the use of 68Ga-ABY-025 PET as a non-invasive method for whole-body HER2-receptor quantification. The study involved 40 patients confirmed to have HER2-positive status—19 with primary breast cancer and 21 with metastatic forms of the disease (with an average of three prior treatments). For each patient, baseline evaluations were carried out using 68Ga-ABY-025 PET/CT, alongside another type of PET/CT scan known as 18F-FDG and core-needle biopsies from selected lesions. Following two rounds of therapy, 18F-FDG PET/CT scans were conducted once again to examine changes in the way the tumor lesions metabolize sugar.

The scientists recorded tracer uptake in up to five of the largest lesions in each patient, including those from which biopsies were taken. They then compared these standardized uptake values from the 68Ga-ABY-025 PET/CT scans with biopsy-confirmed HER2 status and observed changes in tumor metabolism. The study revealed that 68Ga-ABY-025 PET/CT effectively quantified HER2 levels, and this uptake had a significant correlation with the metabolic response in patients, notably in those dealing with metastatic breast cancer. Moreover, the research showed that patients who had undergone more rounds of previous treatments needed higher levels of 68Ga-ABY-025 to trigger a metabolic response.

“The ability of 68Ga-ABY-025 PET/CT to provide a whole-body visualization of HER2 expression and to predict metabolic response is advantageous and exceeded the biopsy-based approach for metastatic breast cancer patients,” said Ali Alhuseinalkhudhur, MD, PhD candidate in the Department of Immunology, Genetics, and Pathology at Uppsala University. “HER2-based imaging tools might provide a solution in situations where biopsies cannot be performed safely or when biopsy results are inconsistent. In addition, a PET-based approach to evaluate the appropriateness of targeted therapy might help avoid unnecessary side effects and might provide a more personalized opportunity for timely therapy corrections.”

Related Links:
Uppsala University

Gold Supplier
Ultrasound System
Gold Supplier
Electrode Solution and Skin Prep
Gold Supplier
CR Reader
X-Ray Meter

Print article



view channel
Image: Intelligent NR provides high-quality diagnostic images containing significantly less grainy noise (Photo courtesy of Canon)

AI-Driven DR System Produces Higher Quality Images While Limiting Radiation Doses in Pediatric Patients

Ionizing radiation is a fundamental element in producing diagnostic X-rays, yet it's widely acknowledged for its cancer risk potential. Digital projection radiography, a vital imaging modality, accounts... Read more


view channel
Image: The researchers are using MRI-guided radiation therapy that pairs daily MRIs with radiation treatment (Photo courtesy of Sylvester)

AI Technique Automatically Traces Tumors in Large MRI Datasets to Guide Real-time Glioblastoma Treatment

Treating glioblastoma, a prevalent and aggressive brain cancer, involves the use of radiation therapy guided by CT imaging. While this method is effective in targeting radiation, it doesn't provide real-time... Read more


view channel
Image: The HydroMARK Plus Breast Biopsy Site Marker is an Innovation for tissue marker displacement (Photo courtesy of Mammotome)

Innovative Biopsy Marker Provides Clinicians with Long-Term Ultrasound Visibility

Ultrasound is the preferred choice for core biopsy as it provides a real-time view of both the lesion and needle, enabling clinicians to make prompt decisions for their patient’s benefit and improve procedural... Read more

General/Advanced Imaging

view channel
Image: The innovative technology is cheaper and safer than common cancer diagnostic tools (Photo courtesy of University of Waterloo)

Innovative Technology Detects Early-Stage Breast Cancer in Two Minutes

Breast cancer is the second-most common cancer and among the second-leading causes of death from cancer for women. The sooner a malignant tumor is detected, the higher the chances of survival in breast... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Attendees can discover innovative products and technology in the RSNA 2023 Technical Exhibits (Photo courtesy of RSNA)

RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More

The 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA, Oak Brook, IL, USA) to be held in Chicago, Nov. 26 to 30 is all set to offer a vast array of medical... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.